BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lenza MP, Atxabal U, Oyenarte I, Jiménez-Barbero J, Ereño-Orbea J. Current Status on Therapeutic Molecules Targeting Siglec Receptors. Cells 2020;9:E2691. [PMID: 33333862 DOI: 10.3390/cells9122691] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Constant O, Maarifi G, Blanchet FP, Van de Perre P, Simonin Y, Salinas S. Role of Dendritic Cells in Viral Brain Infections. Front Immunol 2022;13:862053. [DOI: 10.3389/fimmu.2022.862053] [Reference Citation Analysis]
2 Wielgat P, Niemirowicz-Laskowska K, Wilczewska AZ, Car H. Sialic Acid-Modified Nanoparticles-New Approaches in the Glioma Management-Perspective Review. Int J Mol Sci 2021;22:7494. [PMID: 34299113 DOI: 10.3390/ijms22147494] [Reference Citation Analysis]
3 Ibarlucea-Benitez I, Weitzenfeld P, Smith P, Ravetch JV. Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity. Proc Natl Acad Sci U S A 2021;118:e2107424118. [PMID: 34155121 DOI: 10.1073/pnas.2107424118] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Shipunov I, Kupaev V. Glycome assessment in patients with respiratory diseases. Translational Metabolic Syndrome Research 2022. [DOI: 10.1016/j.tmsr.2022.02.001] [Reference Citation Analysis]
5 Lim J, Sari-Ak D, Bagga T. Siglecs as Therapeutic Targets in Cancer. Biology (Basel) 2021;10:1178. [PMID: 34827170 DOI: 10.3390/biology10111178] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
6 Forgione RE, Nieto FF, Di Carluccio C, Milanesi F, Fruscella M, Papi F, Nativi C, Molinaro A, Palladino P, Scarano S, Minunni M, Montefiori M, Civera M, Sattin S, Francesconi O, Marchetti R, Silipo A. Conformationally Constrained Sialyl Analogues as New Potential Binders of h-CD22. Chembiochem 2022;:e202200076. [PMID: 35313057 DOI: 10.1002/cbic.202200076] [Reference Citation Analysis]
7 Karmakar J, Mukherjee K, Mandal C. Siglecs Modulate Activities of Immune Cells Through Positive and Negative Regulation of ROS Generation. Front Immunol 2021;12:758588. [PMID: 34804046 DOI: 10.3389/fimmu.2021.758588] [Reference Citation Analysis]
8 Bhattacherjee A, Daskhan GC, Bains A, Watson AES, Eskandari-Sedighi G, St Laurent CD, Voronova A, Macauley MS. Increasing phagocytosis of microglia by targeting CD33 with liposomes displaying glycan ligands. J Control Release 2021;338:680-93. [PMID: 34517042 DOI: 10.1016/j.jconrel.2021.09.010] [Reference Citation Analysis]
9 Gonzalez-Gil A, Schnaar RL. Siglec Ligands. Cells 2021;10:1260. [PMID: 34065256 DOI: 10.3390/cells10051260] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Liu Y, Nicklin P, He Y. New Targets for Antiviral Therapy: Inhibitory Receptors and Immune Checkpoints on Myeloid Cells. Viruses 2022;14:1144. [PMID: 35746616 DOI: 10.3390/v14061144] [Reference Citation Analysis]
11 Anwar MT, Kawade SK, Huo Y, Adak AK, Sridharan D, Kuo Y, Fan C, Wu H, Lee Y, Angata T, Lin C. Sugar nucleotide regeneration system for the synthesis of Bi- and triantennary N-glycans and exploring their activities against siglecs. European Journal of Medicinal Chemistry 2022. [DOI: 10.1016/j.ejmech.2022.114146] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]